title: Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
abstract: Decitabine and CHG regimen (low-dose cytarabine and homoharringtonine with G-CSF) have been used for treating higher risk myelodysplastic syndrome (MDS). In this study, we retrospectively compared the efficacy and toxicity of the two regimens in 132 MDS patients. Complete remission (CR) was not significantly different between the groups (27.1% with decitabine vs. 30.6% with CHG, p = 0.657). The CR rate with decitabine (58.8%) was significantly higher than that with CHG (7.7%) (p = 0.007) among the patients with poor karyotypes. Five of 23 (21.7%) patients who failed to respond to decitabine achieved CR with CHG, while one of two patients achieved CR with decitabine after failure with CHG. Overall and relapse-free survival were not different between the groups. In conclusion, both decitabine and CHG regimen are effective for higher risk MDS; there is no cross resistance between the regimens. Decitabine might be a better choice for patients with poor karyotypes.
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Lingyun
authors.initials: L
authors.lastname: Wu
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Li
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Chunkang
authors.initials: C
authors.lastname: Chang
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Qi
authors.initials: Q
authors.lastname: He
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Dong
authors.initials: D
authors.lastname: Wu
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Jiying
authors.initials: J
authors.lastname: Su
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Liyu
authors.initials: L
authors.lastname: Zhou
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Luxi
authors.initials: L
authors.lastname: Song
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Chao
authors.affiliation: a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.
authors.forename: Youshan
authors.initials: Y
authors.lastname: Zhao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D000077209:Decitabine; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006248:Harringtonines / Q000008:administration & dosage; D000077863:Homoharringtonine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006248:Harringtonines; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000077863:Homoharringtonine; D000077209:Decitabine; D001374:Azacitidine
keywords: Cytarabine; decitabine; granulocyte colony-stimulating factor (G-CSF); homoharringtonine; myelodysplastic syndromes